PT - JOURNAL ARTICLE AU - Gu, Yian AU - Honig, Lawrence S. AU - Kang, Min Suk AU - Bahl, Aanya AU - Sanchez, Danurys AU - Reyes-Dumeyer, Dolly AU - Manly, Jennifer J. AU - Lantigua, Rafael A. AU - Dage, Jeffrey L. AU - Brickman, Adam M. AU - Vardarajan, Badri N AU - Mayeux, Richard TI - Risk of Alzheimer’s Disease is Associated with Longitudinal Changes in Plasma Biomarkers in the Multiethnic Washington Heights, Inwood Columbia Aging Project Cohort AID - 10.1101/2023.08.11.23293967 DP - 2023 Jan 01 TA - medRxiv PG - 2023.08.11.23293967 4099 - http://medrxiv.org/content/early/2023/08/16/2023.08.11.23293967.short 4100 - http://medrxiv.org/content/early/2023/08/16/2023.08.11.23293967.full AB - INTRODUCTION Alzheimer’s disease (AD) biomarkers can help differentiate cognitively unimpaired (CU) individuals from mild cognitive impairment (MCI) and dementia. The role of AD biomarkers in predicting cognitive impairment and AD needs examination.METHODS In 628 CU individuals from a multi-ethnic cohort, Aβ42, Aβ40, phosphorylated tau-181 (P-tau181), glial fibrillary acid protein (GFAP), and neurofilament light chain (NfL) were measured in plasma.RESULTS Higher baseline levels of P-tau181/Aβ42 ratio were associated with increased risk of incident dementia. A biomarker pattern (with elevated Aβ42/Aβ40 but low P-tau181/Aβ42) was associated with decreased dementia risk. Compared to CU, participants who developed MCI or dementia had a rapid decrease in the biomarker pattern reflecting AD-specific pathological change.DISCUSSION Elevated levels of AD biomarker P-tau181/Aβ42, by itself or combined with a low Aβ42/Aβ40 level, predicts clinically diagnosed AD. Individuals with a rapid change in these biomarkers may need close monitoring for the potential downward trajectory of cognition.Research in ContextSystematic Review: Few studies have evaluated the clinical application of AD blood-based biomarkers longitudinally as antecedent risk predictors. Data from multiethnic populations are even more limited. How preclinical trajectories of blood-based biomarkers are related with the risk of developing clinically diagnosed MCI or AD is largely unknown.Interpretation: High circulating level of P-tau181/Aβ42, by itself or combined with a low level of Aβ42/Aβ40, may predict development of incident clinical AD. Biomarkers levels of P-tau181, P-tau181/Aβ42, and NfL increase with age even among individuals who remain cognitively healthy. A rapid change in biomarkers may indicate the individuals in the active trajectory to develop clinically diagnosed MCI or AD.Future Directions: Larger studies or meta-analyses are needed to examine whether the predictive utility of blood-based biomarkers for AD differs across racial/ethnic groups. Well-designed studies are needed to evaluate the optimal duration between repeated measures of biomarkers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Institute on Aging grants PO1AG007232, R01AG037212, RF1AG054023, AG037212, AG072474, AG066107, AG059013, and by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant No. UL1TR001873. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review boards of Columbia University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.